season
pandem
influenza
infect
import
public
health
effect
strategi
reduc
morbid
mortal
associ
influenza
global
health
intern
guidelin
recommend
fever
treatment
influenza
infect
qualif
may
help
unlik
caus
harm
howev
fever
benefici
adapt
physiolog
respons
infect
may
confer
surviv
benefit
fact
treat
fever
could
anim
treatment
drug
increas
mortal
infect
effect
drug
therapi
anim
model
influenza
infect
found
increas
risk
mortal
odd
ratio
ci
human
paracetamol
prolong
infect
varicella
impair
immun
previou
random
trial
effect
therapi
human
influenza
infect
number
potenti
mechan
treatment
paracetamol
may
influenc
outcom
influenza
infect
temperatur
within
human
febril
rang
enhanc
activ
cytotox
lymphocyt
cytokin
interferon
ifn
paracetamol
inhibit
polymorphonuclear
leucocyt
function
vitro
effect
augment
human
febril
prophylact
paracetamol
time
vaccin
impair
humor
immun
respons
opsonophagocyt
activ
infant
appar
independ
effect
influenza
virus
replic
upper
respiratori
tract
natur
occur
influenza
strain
infect
human
temperatur
sensit
inhibit
replic
temperatur
within
physiolog
febril
rang
degre
temperatur
sensit
one
characterist
determin
trial
investig
effect
paracetamol
viral
shed
clinic
symptom
adult
influenza
infect
hypothes
regular
administr
paracetamol
confirm
influenza
infect
associ
prolong
viral
shed
wors
symptom
prolong
ill
durat
primari
outcom
variabl
area
curv
auc
quantit
pcr
influenza
viral
load
baselin
day
particip
pcr
adjust
baselin
temperatur
paracetamol
use
h
prior
random
chosen
primari
outcom
variabl
may
predictor
sever
influenza
infect
predictor
risk
hospit
secondari
viral
outcom
variabl
also
applic
particip
pcr
proport
decreas
viral
load
day
proport
undetect
viral
load
day
viral
cultur
day
secondari
clinic
outcom
applic
particip
regardless
influenza
statu
temperatur
profil
daili
maximum
daili
mean
auc
temperatur
first
h
time
resolut
ill
total
daili
symptom
score
auc
health
statu
va
day
past
research
report
standard
deviat
sd
auc
quantit
pcr
influenza
viral
load
day
use
mean
sd
analysi
random
control
trial
therapi
influenza
report
differ
placebo
therapi
anticip
effect
paracetamol
may
half
differ
found
therapi
total
sampl
size
two
treatment
arm
power
detect
differ
type
error
rate
statist
analysi
without
interim
analysi
primari
outcom
variabl
analyz
student
adjust
analysi
carri
analysi
covari
categor
variabl
analyz
calcul
rel
risk
risk
differ
togeth
appropri
ci
analysi
temperatur
symptom
score
auc
va
analysi
varianc
random
group
pcr
influenza
statu
interact
two
predictor
variabl
individu
temperatur
profil
plot
togeth
local
weight
scatter
plot
smoother
cox
proport
hazard
surviv
analysi
use
compar
time
symptom
resolut
sa
version
sa
institut
inc
cari
nc
usa
use
differ
random
group
placebo
minu
paracetamol
primari
outcom
measur
auc
quantit
influenza
pcr
viral
load
baselin
day
ci
p
tabl
estim
differ
adjust
paracetamol
use
past
h
temperatur
baselin
ci
p
tabl
show
viral
load
comparison
individu
time
point
differ
secondari
viral
outcom
variabl
tabl
cytokin
measur
supplementari
tabl
particip
ill
n
differ
paracetamol
placebo
group
maximum
daili
temperatur
tabl
supplementari
fig
mean
daili
temperatur
supplementari
tabl
auc
temperatur
first
h
supplementari
tabl
differ
total
daili
symptom
score
two
group
day
auc
health
statu
va
day
tabl
hazard
ratio
time
resolut
ill
placebo
versu
paracetamol
group
ci
p
fig
interact
random
treatment
whether
influenza
detect
pcr
maximum
daili
temperatur
total
daili
symptom
score
time
resolut
ill
va
tabl
maximum
daili
temperatur
day
higher
pcr
versu
particip
versu
mean
differ
ci
p
signific
differ
pcr
versu
particip
maximum
daili
temperatur
day
symptom
score
time
resolut
ill
va
pcr
particip
mean
sd
maximum
daili
temperatur
day
respect
supplementari
tabl
one
particip
placebo
group
suffer
seriou
advers
event
withdrew
studi
day
one
subject
placebo
group
suffer
exacerb
asthma
requir
oral
prednison
four
particip
receiv
oral
antibiot
three
placebo
group
sinus
n
asthma
n
one
paracetamol
group
tonsil
oseltamivir
discontinu
particip
due
intoler
placebo
group
paracetamol
group
median
interquartil
rang
codein
use
first
h
mg
placebo
paracetamol
group
directli
observ
adher
investig
medicin
initi
inpati
stay
two
particip
placebo
group
four
particip
paracetamol
group
fail
return
bottl
day
adher
day
placebo
group
paracetamol
group
knowledg
first
random
trial
effect
paracetamol
patient
confirm
influenza
infect
regular
daili
administr
maximum
recommend
dose
paracetamol
day
effect
viral
shed
temperatur
clinic
symptom
particip
influenza
infect
difficult
infer
benefit
harm
given
lack
effect
regular
paracetamol
administ
earli
cours
ill
trial
thu
recommend
practic
commun
made
base
find
number
methodolog
issu
consid
interpret
find
particip
random
within
h
symptom
onset
ensur
treatment
initi
earli
cours
ill
small
amount
paracetamol
nsaid
use
particip
random
unlik
clinic
signific
effect
natur
cours
ill
addit
variabl
time
symptom
onset
studi
entri
howev
like
mirror
happen
patient
seek
medic
advic
symptom
despit
random
schedul
larger
number
particip
placebo
group
chronic
respiratori
condit
andor
season
influenza
vaccin
compar
control
group
unclear
extent
characterist
may
influenc
particip
symptom
score
particip
admit
ctu
first
h
trial
period
consequ
period
full
complianc
studi
drug
temperatur
record
complet
accur
adher
medic
discharg
approxim
group
particip
administ
cours
oseltamivir
accord
intern
recommend
manag
influenza
infect
time
protocol
although
may
reduc
ill
sever
viral
load
effect
oseltamivir
would
across
paracetamol
placebo
howev
possibl
use
may
reduc
abil
detect
signific
differ
random
treatment
primari
outcom
patient
recruit
follow
attend
primari
healthcar
clinic
ill
find
generaliz
manag
otherwis
healthi
adult
ill
proven
influenza
infect
commun
number
altern
explan
find
differ
random
group
apart
fact
paracetamol
affect
influenza
outcom
studi
recruit
case
despit
screen
rapid
antigen
test
kit
report
diagnost
specif
influenza
baselin
pernas
sampl
contain
human
rna
indic
lower
expect
result
unlik
due
poor
sampl
techniqu
possibl
specif
rapid
antigen
test
reduc
studi
due
cross
reactiv
respiratori
lower
anticip
number
influenza
case
might
expect
reduc
statist
power
detect
differ
sd
primari
outcom
variabl
substanti
less
anticip
past
research
ci
differ
exclud
differ
expect
detect
half
magnitud
seen
treatment
may
smaller
differ
primari
outcom
variabl
still
clinic
relev
term
clinic
outcom
variabl
paracetamol
signific
effect
whether
measur
daili
maximum
daili
mean
auc
temperatur
h
may
due
part
modest
febril
respons
particip
mean
maximum
temperatur
day
influenza
group
fall
day
due
lack
efficaci
sampl
unabl
test
hypothesi
suppress
fever
paracetamol
influenza
infect
may
harm
find
rais
question
efficaci
paracetamol
influenza
respiratori
infect
previou
studi
paracetamol
proven
influenza
infect
adult
children
found
two
studi
paracetamol
adult
upper
respiratori
tract
infect
one
studi
report
reduct
temperatur
regular
paracetamol
compar
placebo
presum
upper
respiratori
tract
studi
compar
singl
dose
paracetamol
placebo
acut
febril
adult
upper
respiratori
tract
symptom
report
signific
reduct
temperatur
summari
studi
found
regular
administr
paracetamol
effect
viral
shed
temperatur
symptom
ill
durat
patient
influenza
infect
ill
also
treat
oseltamivir
prioriti
undertak
studi
ascertain
profil
routin
use
paracetamol
alon
treatment
presum
influenza
infect
otherwis
healthi
adult
commun
pi
studi
group
would
like
acknowledg
assist
staff
follow
gener
practic
medic
centr
island
bay
medic
centr
karori
medic
centr
kenepuru
accid
medic
clinic
massey
univers
student
health
miramar
medic
centr
newland
medic
centr
onslow
medic
centr
peninsula
medic
centr
ropata
medic
centr
victoria
univers
student
health
wellington
hospit
emerg
depart
would
also
like
thank
studi
particip
time
contribut
studi
dilig
adher
studi
procedur
studi
fund
health
research
council
new
zealand
hrc
hrc
role
design
conduct
studi
collect
manag
analysi
interpret
data
prepar
review
approv
manuscript
decis
submit
paper
public
full
data
set
avail
request
correspond
author
irenebraithwait
mrinzacnz
consent
obtain
particip
data
share
present
data
anonym
risk
identif
minim
